A friend told me, still clearly shellshocked 20 years on, that her mother lived just 12 days after a pancreatic cancer diagnosis. Now research has shown it is giving hope to patients with BRCA pancreatic cancer too. I’m stubborn like that.’ Davi D’Agostino (pictured) has been taking experimental PARP inhibitor, rucaparib after being diagnosed with pancreatic cancer since February 2018. Consultants should now be able to apply to the Cancer Drugs Fund for olaparib for BRCA pancreatic cancer.' 'I'm sure there will be a strong push for full approval, but in the meantime there is also the Cancer Drugs Fund route.

Source: Daily Mail June 08, 2019 21:22 UTC